** Medical equipment maker Agilent Technologies' A.N shares down 2.3% at $100.12
** Jefferies cuts PT to $116 from $135, maintains "hold" rating
** New PT represents 13.2% upside to stock's last close
** "Near-term uncertainty in key end markets like biopharma, China, and business units like nucleic acid solutions division leaves us cautious on the company's ability to outperform against the current setup," Jefferies says
** Brokerage says co feels "pretty good" on tariff dynamics for contract drug manufacturing business, as most deals are structured so that costs for raw materials are passed along i.e., little threat to A's cost profile
** Jefferies sees limited potential for valuation increases until there's clearer visibility into normal growth returning in 2025 and beyond
** Nine of 21 brokerages rate stock "buy" or higher, 12 "hold"; median PT is $142.41 - LSEG data
** Including session's moves, stock down 25.2% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。